The approval of tyrosine kinase inhibitors and checkpoint inhibitors represented a remarkable progression in the therapeutic landscape for the treatment of metastatic renal cell carcinoma (mRCC). Yet, in the ever-evolving landscape of mRCC treatment, real-world data on these agents, including pazopanib, are scarce. The non-interventional PAZOREAL study investigated the effectiveness and safety of pazopanib (first-line), nivolumab (second-line), and everolimus (second- and third-line) in a real-life setting. The multicentric study included 376 mRCC patients who received first-line treatment with pazopanib and assessed time on the drug (primary endpoint), overall survival, best responses, disease control rates, as well as safety signals and health-related quality of life. The median overall time on the drug was 10.0 months, with first-line pazopanib having a median time on drug of 6.3 months. The median overall survival was 35.9 months. The disease control rate for first-line pazopanib was 56.9%. No new safety signals were detected. PAZOREAL provides valuable real-world data for first-line treatment with pazopanib.
Cancers. 2022 Nov 08*** epublish ***
Christian Doehn, Martin Bögemann, Viktor Grünwald, Manfred Welslau, Jens Bedke, Martin Schostak, Thomas Wolf, Rainer Ehneß, Elisa Degenkolbe, Stefanie Witecy, Peter J Goebell
Urologikum Lübeck, 23566 Lübeck, Germany., Department of Urology, University of Münster Medical Center, 48149 Münster, Germany., Department of Internal Medicine (Tumor Research) and Department of Urology, West German Cancer Center, University Hospital Essen, 45147 Essen, Germany., Klinikum Aschaffenburg, Hämato-Onkologische Schwerpunktpraxis, 63739 Aschaffenburg, Germany., Department of Urology, University Hospital Tübingen, 72076 Tübingen, Germany., Department of Urology, Urooncology, Robot-Assisted and Focal Therapy, University Hospital Magdeburg, 39120 Magdeburg, Germany., Outpatient Centre for Oncology, 01307 Dresden, Germany., Novartis Pharma GmbH, 90429 Nürnberg, Germany., APOGEPHA Arzneimittel GmbH, 01309 Dresden, Germany., Department of Urology, University Hospital Erlangen, 91054 Erlangen, Germany.